Healius shares soar as CEO exits
Make us a preferred source
Make us a preferred source on Google
More news: Healius shares surged 13.5% to $1.28 by 12:30pm AEDT on news of the immediate exit of CEO and managing director Maxine Jaquet.
The pathology services provider also announced that it would commence a "wide-ranging strategic review of the company's structure and assets".
Healius CEO Maxine Jaquet quits ahead of strategic review
The news: Maxine Jaquet has resigned as Healius CEO and managing director with immediate effect, and will be replaced by the company's chief financial officer Paul Anderson.
The numbers: Jaquet joined Healius in 2015, serving as CFO from August 2019, until her promotion to CEO and managing director in March 2023. Anderson replaced Jaquet as group CFO in March last year, following leadership roles at Network 10 and ViacomCBS.
The context: The Sydney-based pathology services provider also announced today that it would commence a "wide-ranging strategic review of the company's structure and assets", engaging investment banking advisors to help undertake the review alongside Healius' board and management.
Anderson will lead the review, which the company said is aimed at "maximising shareholder value in a changing diagnostics market."
Healius' interim chair Kate McKenzie, appointed in November last year after the resignation of permanent chair Jenny Macdonald, thanked Jaquet for leading Healius through a "difficult period for medical diagnostic companies post-Covid".
What they said: McKenzie said: "Maxine brought fresh talent into the executive ranks, led the sale of medical centres, and worked diligently to streamline our operations and integrate acquisitions such as Agilex".
"We will now undertake a methodical review of Healius' operations to ensure they are structured in the optimal way to benefit our millions of customers and our shareholders," she said.
The source: ASX announcement
